Because the panel is mechanistically interpretable, it also generates hypotheses for combinations, such as pairing PD-1 blockade with therapies enhancing antigen presentation or reactive oxygen species (ROS)-mediated tumor killing, while complementing established markers like PD-L1 CPS and circulating tumor DNA (ctDNA) (24). This evidence concerns the gene PDCD1 and neoplasm.